Skip to main content
CellaVision logo

CellaVision — Investor Relations & Filings

Ticker · CEVI ISIN · SE0000683484 LEI · 529900IUBZBZ0HXFJ114 ST Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2022-01-13 Regulatory Filings
Country SE Sweden
Listing ST CEVI

About CellaVision

https://www.cellavision.com/

CellaVision is a medical technology company that provides digital solutions for cell morphology in hematology. The company specializes in automating and standardizing the analysis of blood and other body fluids for both human and veterinary applications. Its core offerings include a complete system of analyzers, instruments, software, and reagents designed for hematology laboratories of all sizes. By utilizing patented technology that integrates automated microscopy, advanced image analysis, and artificial intelligence, CellaVision's systems digitize the traditional manual review of blood smears. This automation enhances laboratory workflow efficiency, improves diagnostic accuracy, and facilitates remote collaboration among healthcare professionals, advancing diagnostic certainty.

Recent filings

Filing Released Lang Actions
CellaVisions CFO Magnus Blixt lämnar bolaget
Regulatory Filings Classification · 1% confidence The document is a short announcement (2935 characters) stating that the CFO, Magnus Blixt, is leaving the company to take a CEO role elsewhere, and that the search for a replacement will begin immediately. The text explicitly mentions that the information is being made public according to the EU Market Abuse Regulation ('EU:s marknadsmissbruksförordning'). This format—a brief announcement of a significant internal change (management departure) released under regulatory obligation—is characteristic of a general regulatory filing or announcement, rather than a detailed financial report (like 10-K or IR) or a specific management change report (MANG, which usually details the appointment, not just the departure). Since it is a mandatory disclosure under market abuse rules that doesn't fit perfectly into the other specific categories (like DIRS, DIV, or DEF 14A), the most appropriate general category for mandatory regulatory disclosures that don't fit elsewhere is RNS (Regulatory Filings).
2022-01-13 Swedish
Magnus Blixt leaves his position as CFO of CellaVision AB
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding the departure of the Chief Financial Officer (CFO), Magnus Blixt, and his subsequent move to another company. This type of personnel change concerning senior management directly maps to the 'Board/Management Information' category. The text explicitly details the resignation and the search for a successor. The document length is relatively short (2916 chars) and it includes a final section referencing EU Market Abuse Regulation compliance and an attachment, suggesting it is an official regulatory disclosure about management change, not a comprehensive financial report like a 10-K or IR. Therefore, the most appropriate classification is MANG.
2022-01-13 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report for CellaVision, covering the period of July-September 2021 (Q3). It contains detailed financial statements, including income statements, cash flow analysis, and management commentary on business performance, regional market developments, and operational updates. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a full 10-K as it covers only a quarterly period. Therefore, it is classified as an Interim/Quarterly Report. Q3 2021
2021-10-22 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'CellaVision Interim report Q3 January - September 2021'. It contains comprehensive financial statements, including income statements, cash flow analysis, and detailed management commentary on performance for the third quarter and the nine-month period. It is not a short announcement or a certification, but the full interim report itself, fitting the definition of an Interim/Quarterly Report (IR). 9M 2021
2021-10-22 English
Earnings Release 2021
Earnings Release Classification · 1% confidence The document provides detailed financial figures for the period April-June 2021 (Q2) and January-June 2021 (six months), including Net Sales, EBITDA, margins, cash flow, and management commentary on performance, strategy, and acquisitions (like Clearbridge BioPhotonics). This structure, covering a specific interim period with detailed financial tables and MD&A-style commentary, strongly indicates a comprehensive interim financial report. Since it covers a period shorter than a year (Q2 and H1), it fits the definition of an Interim / Quarterly Report (IR), rather than the full Annual Report (10-K). It is not merely an announcement (RPA) as it contains the full substance of the results. Q2 2021
2021-07-20 Swedish
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 1% confidence The document is titled 'CellaVision Interim report Q2 January - June 2021'. It contains comprehensive financial statements, including income statements, cash flow analysis, and management commentary on business performance for the specified period. It is not an announcement of a report (RPA) but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2021
2021-07-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.